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Papillary thyroid carcinoma (PTC) is the most common endocrine gland malignancy and occurs frequently due
to the radiation exposure. PTC is characterized by the paracentric inversion in chromosome 10 leading to the fu-
sion of RET with several genes present in thyroid named PTC. The RET/PTCs junction oncogenes are present in
around 80 % of papillary thyroid carcinoma, the most frequent ones are RET/PTC1 and RET/PTC3. Interesting-
ly, RET/PTCs are found only in the tumour cells and not in the surrounding normal tissues, therefore, they repre-
sent a good target for RNA interference strategies. We aimed, on the one hand, to inhibit dedifferentiation due to
the RET/PTC junction oncogene by siRNA and, on the other hand, to investigate a role of Wnt/-catenin pathway
in the regulation of a tissue-specific transcription factor, the thyroid transcription factor-1 (TTF-1) essential for
the differentiation of the thyroid. In this paper we summarised our main results obtained during eight years that
pointed a new therapeutic strategy for papillary thyroid carcinoma.
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Introduction. Junction oncogenes are the consequence
of genomic rearrangements, especially translocations,
leading to the intragenic gene fusion found in around
20 % of total cancers. First, they were described in chro-
nic myeloid leukemia where a translocation between
chromosome 9 and 21 t(9;22)(q34;q11) occurs leading
to the junction of brc-abl genes. Nowadays, they are
well described in sarcoma (Ewing sarcoma) and in car-
cinomas such as papillary thyroid carcinoma (PTC). In
fact, thyroid carcinomas are the most common endocri-
ne gland malignancy that can be classified according to
their histopathological characteristic [1]. Rearrangement
of theRET gene, also known asRET/PTC rearrangement,
is the most common genetic alteration identified to date
in thyroid papillary carcinomas. The possibility to inhi-
bit the expression of an oncogene at the mRNA level, in-
stead of blocking the function of the gene product, has
elicited for a long time a great interest as the potential
therapeutic applications are obvious. Therefore, RNA
interference offers promising new opportunities to tar-
get very specifically the genes deregulated in PTC can-
cers carrying the RET/PTC junction oncogenes.
It is well known that cancer cell transformation by
the expression of an oncogene may act in two different
ways, which can be simultaneous. First, the oncogene is
able to enhance the cell growth by affecting different
proteins involved in cell proliferation; second, the onco-
gene blocks the cell death. In thyroid carcinoma, one of
the proteins involved in the cell proliferation is the thy-
roid transcription factor-1 (TTF-1). TTF-1 is only ex-
pressed in the thyroid follicular cells and together with
Paired box gene-8 (PAX-8) controls the expression of
thyroglobulin (Tg), thyroperoxydase (TPO), thyrotropin
receptor (TSH) and the sodium/iodide symporter (NIS),
calcitonin and major histocompatibility complex class
I genes in the thyroid [2–4]. In this way, the combina-
tion of these two factors plays a role in the expression
of the thyroid-specific phenotype.
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Since 2008 our aim was to offer a personalized treat-
ment for cancer patients with junction oncogenes by: i)
restoring differentiation by knocking down junction on-
cogenes using small interference RNA strategy, and ii)
maintaining the expression of genes involved in thyroid
differentiation. In the following paragraphs the strategi-
es that we followed to reach our goal will be described
and the biological relevance of the results obtained du-
ring the last years will be discussed.
RET/PTC junction oncogenes and papillary thy-
roid carcinomas (PTC). Papillary thyroid carcinomas
are characterized by gene rearrangements affecting the
RET (rearranged during transfection) proto-oncogene,
which is located on chromosome 10q11.2 and codes for
a cell membrane tyrosine kinase receptor [5]. This gene
plays a role in the regulation of cell growth, survival,
differentiation and migration [6]. In PTC, RET fuses
with different ubiquitous genes to give various RET/
PTC fusion rearrangements, that results in an abnormal
expression of the chimeric RET protein which is con-
stitutively activated in follicular cells [7]. To date, 13
different fusion patterns have been reported between
the RET and genes located on different chromosomes
[8]. RET/PTC1 and RET/PTC3 are the major variants,
whereas the others are very rare and have little clinical
significance. RET/PTC1 results from the fusion of RET
with H4 gene (also known as CCDC6), and RET/PTC3
arises fromRET fusion withELE1 gene also designated
as nuclear receptor co-activator 4; NCOA4, RFG or
ARA70 [9]. The spatial proximity of RET gene with
CCDC6 (10q21) or ELE1 (10q11.2) during thyrocyte
interphase explains theRET/PTC1 orRET/PTC3 forma-
tion [10].
The prognosis of PTC is generally good, depending
on the biological behaviour of the tumour and appro-
priate initial treatment [11, 12] which includes total thy-
roidectomy and functional lymph node dissection, fol-
lowed by radioiodine therapy and rarely, radiotherapy
or chemotherapy.
However, a considerable number of patients, appro-
ximately 30 %, as shown after 30 years of follow-up,
have recurrent disease. This constitutes an area of im-
portant research on emerging therapies such as using
small interfering RNA (siRNA) to target the RET/PTC
fusion oncogene which is present only in the tumour cells
and not in the surrounding normal cells.
In order to introduce a new pharmacological ap-
proach with siRNA against the RET/PTC1 and RET/
PTC3 junction oncogenes we first designed siRNAs wi-
thin the junction sequence according to the «method of
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Fig 1. Summary of the main results obtained in vitro after knocking-down by siRNA RET/PTC junction oncogene. Cell lines expressing RET/PTC1
(A) or RET/PTC3 (B) were transfected with 50 nM of siRNA CT, siRNA RET/PTC1 or siRNA RET/PTC3. A
1
and B
1
– the expression of RET/PTC1
or RET/PTC3 mRNA levels was analyzed by real time RT-PCR (RT-qPCR) and recorded as % of modification of treated cells with siRNA RET/PTC1
or RET/PTC3 compared to the siRNA control. A
2
and B
2
– RET protein level in cells transfected with siRNA control (left bands) and transfected with
siRNA RET/PTC1 or siRNA RET/PTC3 (right bands) at 50 nM. Proteins were extracted and analyzed by Western blot using Ret antibody. A
3
and
B
3
– the viability of cells expressing RET/PTC1 (A) or RET/PTC3 (B) was evaluated by MTT assay after 72 h incubation with therapeutic siRNAs
(siRNA RET/PTC1 or siRNA RET/PTC3) or siRNA control at 50 nM concentration. The number of viable cells was measured and 100 % cell viabi-
lity corresponds to the number of living cells incubated with transfecting agent only. A decrease of cell viability was observed in transfected cells
with siRNA therapeutic siRNAs compared to those transfected with the siRNA control. A
4
– apoptosis was evaluated with an in situ TUNEL method.
To determine the apoptotic index one thousand cells were counted on each slide and the average number of apoptotic cells was established. A 6-fold
increase was observed when cells were transfected with the siRNA RET/PTC1 compared to the siRNA control, this testifying apoptosis. B
5
– Wes-
tern blot of cleaved caspase-3 was performed 72 h after RP3 cells (expressing RET/PTC3 junction oncogene) transfected with siRNA RET/PTC3 or
siRNA control at 50 nM. Increase of cleaved caspase-3 is clearly observed once cells were transfected with siRNA RET/PTC3, this also testified
apoptosis
scoring» developed by Reynolds et al. [13]. Four siRNAs
were designed for each sequence. The most efficient one
that gave more than 80 % of mRNA inhibition followed
by a drastic decrease in the protein content was eligible
for further studies. Moreover, siRNA RET/ PTC1 or
siRNA RET/PTC3 are able to inhibit only their own jun-
ction oncogene showing that a specific fusion sequence
is required to target the junction oncogene. From a bio-
logical point of view, both siRNA RET/PTC (1 and 3)
showed significant inhibitory effects on cell viability
and on invasion/migration along with blockage of the cell
cycle at G0/G1 phase. Additionally, we observed apopto-
sis induction with caspase-3 and PARP1 cleavage [14,
15]. Fig. 1 summarizes the main results obtained.
However, in vivo delivery of siRNA is a key challen-
ge because the biological efficacy of siRNAs is hampe-
red by their short plasmatic half-life due to a poor sta-
bility in the biological fluids and by their low intracel-
lular penetration due to their highly hydrophilic charac-
ter. So far, a wide variety of approaches have been em-
ployed to deliver siRNA in vivo including viral-vector
based and non-viral delivery systems, such as liposo-
mes, nanoparticles, lipophilic conjugates, polymers and
cell penetrating peptides [16], however, the safety of
these vectors is questionable [17]. Therefore, recently
we have conceived a new strategy to deliver siRNAs,
based on their conjugation to squalene (SQ), a natural
and nonionic biocompatible lipid [18]. This concept ter-
med «squalenoylation» consists in covalent binding of
the squalene with siRNA RET/PTC1 or RET/PTC3 at
the 3'-terminus of the sense strand via maleimide-sulf-
hydryl chemistry. Remarkably, the linkage led to an am-
phiphilic molecule that self-organized in water as
siRNA-SQ RET/PTC (1 or 3) nanoparticles (NPs). The-
se NPs were used for in vivo studies. Interestingly, the
siRNA RET/PTC (1 or 3)-SQ NPs injected intravenous-
ly or intratumoraly in nude mice were able to reduce tu-
mour growth, inhibit oncogene and oncoprotein expres-
sions, induce apoptosis and partially restore differentia-
tion (decrease in Ki67) [15, 19] (Fig. 2). Taken to-
gether these results showed that the vectorized siRNAs
against the RET/PTC junction oncogene could be used
in clinical studies to assess their effects in patients with
the RET/PTC junction oncogene.
Regulation of TTF-1 byWnt/-catenin pathway.
TTF-1 is a tissue specific transcription factor expressed
in epithelial cells of the thyroid and lunga, as well as in
certain areas of the brain [20]. TTF-1 is a useful immu-
nohistochemical marker in the diagnosis of thyroid or
lung cancers [21–23]. TTF-1 is well detectable in papil-
lary carcinomas and absent in anaplastic carcinomas,
therefore it was used as a marker to distinguish between
these two types of thyroid neoplasms [23, 24]. The Wnt
signaling pathway plays a critical role in the develop-
ment and organogenesis [25] but this pathway has also
emerged as a critical pathway in carcinogenesis [26].
Furthermore, many -catenin targets have been shown
to play an important role in cancer including c-myc, cyc-
lin D1, matrix metalloproteases, CD44, homeodomain
containing genes [27].
The Wnt/-catenin pathway activation is defined by
three molecules, a constitutively active serine kinase,
called glycogen synthase kinase-3 (GSK-3), adenoma-
tous polyposis coli (APC) and the scaffolding protein
Axin, associated with -catenin in the cytoplasm. -ca-
tenin is usually phosphorylated by GSK-3 and is sub-
sequently targeted by ubiquitination for rapid proteaso-
me degradation. In the presence of Wnt ligands, Frizz-
led receptor is activated in the membrane, which leads
to the inactivation of GSK-3 through intermediary mo-
lecules including the dishevelled and GSK-3 binding
protein. This results in the accumulation of -catenin in
the cytoplasm and its subsequent translocation to the
nucleus, where it forms a complex with the nuclear trans-
criptional regulator T-cell factor/lymphoid enhancer
factor (TCF/LEF), finally causing the binding of down-
stream genes and promotion of transcriptional activation.
It has been suggested by many authors that the -
catenin may play a direct role in the dedifferentiation
commonly observed in the late-stage disease of PTC
[28]. However, the role of canonical Wnt signaling in
TTF-1 regulation remains undetermined. Our aim was to
investigate whether the Wnt/-catenin pathway would
regulate TTF-1 expression in a papillary thyroid carci-
noma model and to examine the mechanism through
which this regulation takes place. Using immunocyto-
chemical analysis, RT-qPCR and Western blots studies
we found that TTF-1 as well as the major Wnt pathway
components were expressed in TPC-1 cells. Knocking-
down the Wnt/-catenin components by siRNAs in-
hibited both TTF-1 transcript and protein expression.
The activation of Wnt signalling by lithium chloride or
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Fig 3. Summary of the main results obtained concerning the regulation of TTF-1 by Wnt/-catenin pathway: A – strategies used to assess the regula-
tion of TTF-1 by Wnt/-catenin pathway. Two strategies were used; the first one consists in inhibiting the molecular partners of Wnt/-catenin by
siRNA against the major molecular partners LRP6, disheveled (Dsh), -catenin (-cat) and TCF. A decreased of mRNA and protein TTF-1 levels
were observed. The second strategy is to mimic the activation of these signaling pathways by LiCl or SB216763, both known as inhibitors of
GSK-3 activity. An increase of TTF-1 mRNA and protein was observed. By promoter experiments followed by chromatine immunoprecipitation
(ChIP) assays an active TCF responsive element was found between 798 and 792 bp upstream the ATG start site. B– colocalisation of TCF-4 and
TTF-1 transcription factor. Immunochemical studies showed a perfect colocalisation of TCF-4 and TTF-1 in the same area of papillary thyroid car-
cinoma tissues
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Fig. 2. Summary of the main results obtained in vivo after squalenisation of siRNA. A – squalenisation of siRNAs (the squalene was covalently
coupled to therapeutic siRNAs (siRNA RET/PTC1 or to siRNA RET/PTC3) or to siRNA Control modified in the 3’-end sense strand; the bio-
conjugation is able to give nanoparticles in water of above 160 nm of diameter); B – in vivo studies (when the siRNAs-SQ nanoparticles are
injected into nude mice a regression of tumor growth was observed paralleled with a decreases of mRNA RET/PTCs mRNA levels and of RET
protein content; moreover, a cleavage of caspase-3 and a decrease of Ki67 dedifferentiation marker were observed in the treated tumors)
SB216763 induced the TTF-1 gene and protein ex-
pression. The functional promoter studies and ChIP
analysis showed that the Wnt/-catenin pathway exerts
its effect by means of the binding of -catenin to TCF/
LEF transcription factors at (-798, -792 bp) in TTF-1
promoter. Moreover, immunohistological studies per-
formed on human normal thyroid and PTC tissues re-
vealed that the TTF-1 and transcription factor 4 (TCF4)
proteins showed a colocalisation of -catenin and TCF-
4 within the papillary cells [29] (Fig. 3). This study sug-
gests that TTF-1 is a direct transcriptional target of the
Wnt/-catenin signalling pathway and could be investi-
gated in association with a targeted treatment against
theRET/PTC oncogene in the case of aggressive or per-
sistent PTC.
Conclusions. These studies have a double impact.
From a fundamental point of view, this work demonst-
rates for the first time that Wnt/-catenin regulates
TTF-1 in the papillary thyroid cancer cells through -ca-
tenin-binding to the TCF/LEF-responsive element pre-
sent in TTF-1 promoter. We suggest that Wnt/-catenin
pathway contributes to the fine-tuning of TTF-1 expres-
sion and could have different biological consequences
according to the cellular context. We speculate that nor-
mal Wnt/-catenin expression maintains the basal TTF-
1 expression and differentiated cell state, whereas the
activation of Wnt/-catenin signaling would have an ef-
fect on tumour progression (occurs consequently to
mutations within the molecular Wnt signaling partners
leading to the continuous activation of -catenin and
thus of TTF-1). From a medical point of view, we hope
that the administration of LiCl or other GSK-3 inhibi-
tors or Wnt modulators will stimulate the expression of
TTF-1 and, as a consequence, promote the thyroid cells
differentiation in pathologies where the TTF-1 expres-
sion is lacking or weak. This is of great interest for
thyroid or lung cancers where the TTF-1 expression is
crucial to maintain cell differentiation.
Concerning the significance of siRNA RET/PTC-
SQ NPs, we succeeded in establishing and delivering
siRNAs against the RET/PTC1 and RET/PTC3 junction
oncogenes. This would have clinical application for pa-
tients with papillary thyroid carcinoma but further phar-
macological and clinical investigations should be done
to set-in the remedy of thyroid carcinoma.
We speculate that if we want to offer personalized
treatments for cancer patients with junction oncogenes
we should counteract dedifferentation due to the RET/
PTC junction oncogenes by knocking down the oncoge-
nic fusion genes products by siRNA and supplement, if
necessary, this targeting therapy by modulating the ex-
pression of transcription factor involved in the tumor
progression.
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Íåîáõîäèìîñòü âîçäåéñòâèÿ íà ñëèòûé îíêîãåí RET / PTC3
è Wnt/-êàòåíèí ñèãíàëüíûé ïóòü ïðè ëå÷åíèè ïàïèëëÿðíîãî
ðàêà ùèòîâèäíîé æåëåçû: ðåçóëüòàòû âîñüìèëåòíåé ðàáîòû
Ë. Ìàññàä-Ìàññàä
Ðåçþìå
Ïàïèëëÿðíûé ðàê ùèòîâèäíîé æåëåçû (PTC) ÿâëÿåòñÿ íàèáîëåå
ðàñïðîñòðàíåííûì çëîêà÷åñòâåííûì íîâîîáðàçîâàíèåì ýíäî-
êðèííûõ æåëåç è ÷àñòî âûçûâàåòñÿ îáëó÷åíèåì. PTC õàðàêòåðè-
çóåòñÿ ïàðàöåíòðè÷åñêîé èíâåðñèåé â õðîìîñîìå 10, ïðèâîäÿùåé
ê ñëèÿíèþ ñ RET íåñêîëüêèõ ãåíîâ, ïðèñóòñòâóþùèõ â ùèòîâèä-
íîéæåëåçå èìåíííî ïðè PTC. Ñëèòûå îíêîãåíû RET/PTC îáíàðó-
æåíû ïî÷òè â 80 % ñëó÷àåâ PTC, íàèáîëåå ÷àñòî âñòðå÷àþòñÿ
RET/PTC1 è RET/PTC3, ïðè ýòîì èõ íå âûÿâëåíî â îêðóæàþùèõ
íîðìàëüíûõ òêàíÿõ, âñëåäñòâèå ÷åãî îíè ïðåäñòàâëÿþò ñîáîé
õîðîøóþ ìèøåíü äëÿ ñòðàòåãèé ÐÍÊ-èíòåðôåðåíöèè. Öåëü íà-
øåé ðàáîòû ñîñòîÿëà, ñ îäíîé ñòîðîíû, â èíãèáèðîâàíèè äåäèô-
ôåðåíöèðîâàíèÿ ñ èñïîëüçîâàíèåì ìèÐÍÊ ñëèòîãî îíêîãåíà
RET/PTC è, ñ äðóãîé, – â èññëåäîâàíèè ðîëè Wnt/-êàòåíèí ñèã-
íàëüíîãî ïóòè â ðåãóëÿöèè òêàíåñïåöèôè÷åñêîãî ôàêòîðà
òðàíñêðèïöèè (TTF-1), âàæíîãî äëÿ äèôôåðåíöèàöèè ùèòîâèä-
íîé æåëåçû. Â ýòîé ñòàòüå êðàòêî ïðåäñòàâëåíû îñíîâíûå ðå-
çóëüòàòû, ïîëó÷åííûå â ðåçóëüòàòå âîñüìèëåòíåé ðàáîòû,
óêàçûâàþùèå íà íîâóþ òåðàïåâòè÷åñêóþ ñòðàòåãèþ äëÿ ïàïèë-
ëÿðíîãî ðàêà ùèòîâèäíîé æåëåçû.
Êëþ÷åâûå ñëîâà: êàðöèíîìà ïàïèëëÿðíîãî ùèòîâèäíîé æå-
ëåçû, RET/PTC ñëèòûå îíêîãåíû, ìèÐÍÊ, îïóõîëåâûå êëåòêè.
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Íåîáõ³äí³ñòü âïëèâó íà çëèòèé îíêîãåí RET/PTCÇ ³
Wnt/-êàòåí³í ñèãíàëüíèé øëÿõ ïðè ë³êóâàíí³ ïàï³ëÿðíîãî ðàêó
ùèòîïîä³áíî¿ çàëîçè: ðåçóëüòàòè âîñüìèð³÷íî¿ ðîáîòè
Ë. Ìàññàä-Ìàññàä
Ðåçþìå
Ïàï³ëÿðíèé ðàê ùèòîïîä³áíî¿ çàëîçè (PTC) º íàéðîçïîâñþäæå-
í³øèì çëîÿê³ñíèì íîâîóòâîðåííÿì åíäîêðèííèõ çàëîç, ÿêèé ÷àñòî
ñïðè÷èíÿºòüñÿ îïðîì³íåííÿì. PTC õàðàêòåðèçóºòüñÿ ïàðàöåíòðè-
÷íîþ ³íâåðñ³ºþ â õðîìîñîì³ 10, ÿêà ïðèçâîäèòü äî çëèòòÿ ç RET
äåê³ëüêîõ ãåí³â, ùî ïðèñóòí³ â ùèòîïîä³áí³é çàëîç³ ñàìå ïðè PTC.
Çëèò³ îíêîãåíè RET/PTCÇ çíàéäåíî ìàéæå ó 80% âèïàäê³â PTC, íà-
èé÷àñò³øå çóñòð³÷àþòüñÿ RET/PTCÇ1 ³ RET/PTC3, ïðè öüîìó ¿õ
íå âèÿâëåíî â îòî÷óþ÷èõ íîðìàëüíèõ òêàíèíàõ, âíàñë³äîê ÷îãî âî-
íè ïðåäñòàâëÿþòü ñîáîþ ãàðíó ì³øåíü äëÿ ñòðàòåã³é ÐÍÊ-³íòåð-
ôåðåíö³¿. Ìåòà íàøî¿ ðîáîòè ïîëÿãàëà, ç îäíîãî áîêó, â ³íã³áóâàíí³
äåäèôåðåíö³þâàííÿ ç âèêîðèñòàííÿì ì³ÐÍÊ çëèòîãî îíêîãåíà
RET/PTCòà, ç ³íøîãî, – ó äîñë³äæåíí³ ðîë³ Wnt/-êàòåí³í ñèãíàëü
íîãî øëÿõó â ðåãóëÿö³¿ òêàíèíîñïåöèô³÷íîãî ôàêòîðà òðàí-
ñêðèïö³¿ (TTF-1), âàæëèâîãî äëÿ äèôåðåíö³þâàííÿ ùèòîïîä³áíî¿
çàëîçè. Ó ö³é ñòàòò³ êîðîòêî ïðåäñòàâëåíî îñíîâí³ ðåçóëüòàòè,
îò ðèìàí³ â ðåçóëüòàò³ âîñüìèð³÷íî¿ ðîáîòè, ÿê³ âêàçóþòü íà íîâó
òåðàïåâòè÷íó ñòðàòåã³þ äëÿ ïàï³ëÿðíîãî ðàêó ùèòîïîä³áíî¿ çà-
ëîçè.
Êëþ÷îâ³ ñëîâà: ïàï³ëÿðíèé ðàê ùèòîïîä³áíî¿ çàëîçè, RET/
PTC çëèò³ îíêîãåíè, ì³ÐÍÊ, ïóõëèíí³ êë³òèíè.
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